Other formats:
BibTeX
LaTeX
RIS
@article{1399419, author = {Berthold, Frank and Hömberg, Marc and Proleskovskaja, Inna and Mazánek, Pavel and Belogurova, Margarita and Ernst, Angela and Štěrba, Jaroslav}, article_location = {Philadelphia}, article_number = {5}, doi = {http://dx.doi.org/10.1080/08880018.2017.1373314}, keywords = {Angiogenesis; dose-intense chemotherapy; immunomodulation; metronomic therapy; neuroblastoma}, language = {eng}, issn = {0888-0018}, journal = {Pediatric Hematology and Oncology}, title = {Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma}, volume = {34}, year = {2017} }
TY - JOUR ID - 1399419 AU - Berthold, Frank - Hömberg, Marc - Proleskovskaja, Inna - Mazánek, Pavel - Belogurova, Margarita - Ernst, Angela - Štěrba, Jaroslav PY - 2017 TI - Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma JF - Pediatric Hematology and Oncology VL - 34 IS - 5 SP - 308-319 EP - 308-319 PB - Taylor & Francis SN - 08880018 KW - Angiogenesis KW - dose-intense chemotherapy KW - immunomodulation KW - metronomic therapy KW - neuroblastoma N2 - The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months. The outcome was compared to 274 matched patients with a first recurrence from stage 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification. All were treated with dose-intensive conventional chemotherapy. The study patients experienced 1-3 recurrences and had 1-3 sites involved (osteomedullary, primary tumor, central nervous system, lymph nodes, liver, lungs) before the metronomic therapy started. Two patients in complete remission and three with active refractory disease following recurrence treatment were excluded from the outcome analysis. The curves for secondary event-free and overall survival demonstrated no significant differences. ER -
BERTHOLD, Frank, Marc HÖMBERG, Inna PROLESKOVSKAJA, Pavel MAZÁNEK, Margarita BELOGUROVA, Angela ERNST and Jaroslav ŠTĚRBA. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. \textit{Pediatric Hematology and Oncology}. Philadelphia: Taylor \&{} Francis, 2017, vol.~34, No~5, p.~308-319. ISSN~0888-0018. Available from: https://dx.doi.org/10.1080/08880018.2017.1373314.
|